Orchard Announces Multiple Presentations at 2022 ESGCT Annual Congress Showing the Potential of HSC Gene Therapy in Several Therapeutic Areas
October 10, 2022 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Clinical and pre-clinical data from across the company’s portfolio will be featured in four oral and six poster presentations Co-founder and Chief Executive Officer Bobby Gaspar to give invited talk...
Orchard Therapeutics Announces Multiple Presentations at 2022 SSIEM Annual Symposium Highlighting Neurometabolic Disease Portfolio
August 29, 2022 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced seven presentations from across its neurometabolic portfolio...
Orchard Therapeutics Reports Second Quarter 2022 Financial Results and Reviews Recent Business Highlights
August 04, 2022 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Additional Libmeldy® reimbursement discussions advancing across Europe with product sales totaling $3.1M in Q2 and $8.2M YTD OTL-200 U.S. BLA filing for MLD on track for late 2022 / early 2023 Seven...
Orchard Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Commercial Progress
May 12, 2022 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Product sales for Libmeldy totaled $5.1M for the first two commercial patients treated in Q1 2022 Libmeldy® access and reimbursement expanding with agreements now signed in three major European...
Orchard Therapeutics Announces Presentations at ASGCT 2022 Showcasing Potential of HSC Gene Therapy in Neurodegenerative Disorders and Beyond
May 10, 2022 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined seven presentations from across its platform to be featured at...
Orchard Therapeutics to Webcast Conference Call of First Quarter 2022 Financial Results
May 05, 2022 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast...
Orchard Therapeutics Announces Agreement Enabling Access and Reimbursement for Libmeldy for All Eligible MLD Patients in Germany
May 02, 2022 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached an agreement with Gesetzliche...
Orchard Therapeutics Announces Reimbursement Agreement Making Libmeldy Available for All Eligible MLD Patients in Italy
April 11, 2022 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, April 11, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached another historic reimbursement agreement with...
Orchard Therapeutics Extends Runway into 2024, Focusing HSC Gene Therapy Platform Exclusively on Severe Neurometabolic Diseases and Research Platform
March 30, 2022 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Libmeldy European launch momentum building with multiple MLD patients treated and strong recognition of value proposition; U.S. BLA filing of OTL-200 on track for late 2022 / early 2023 Broad...
Orchard Therapeutics to Webcast Conference Call of Fourth Quarter and Fiscal Year 2021 Financial Results
March 24, 2022 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, March 24, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast...